maxshen8
評論了
1
3
maxshen8
評論了
$Protagonist Therapeutics(PTGX.US$
Protagonist Therapeutics Announces Removal Of FDA Clinical Hold On The Rusfertide Clinical Development Program
Protagonist Therapeutics Announces Removal Of FDA Clinical Hold On The Rusfertide Clinical Development Program
6
7
$NanoViricides(NNVC.US$
納米殺菌劑有限公司(美國紐約證券交易所:NNVC)(「公司」)是基於新型納米醫學技術開發高效抗病毒療法的領導者,今天宣布,其泛冠狀病毒 COVID-19 藥物候選 NV-CoV-2 在標準細胞培養偽病毒測試中發現對 SARS-CoV-2 有效,證明該藥物確實具有廣譜泛型泛型冠狀病毒活性。這種泛型冠狀病毒活性意味著,儘管 SARS-CoV-2 的變種在現場發展,儘管 SARS-CoV-2 變種在現場發展,這是一種對抗當前全球大流行的非常受歡迎的特徵。
在此測試中,候選藥 NV-CoV-2 和 SARS-CoV-2 病毒的 Spike 抗原 S1 特有的陽性對照抗體都抑制了細胞培養研究中 SARS-CoV-2 偽病毒的感染,幾乎具有相同的基線水平。
我們現在已證明,NV-CoV-2 在細胞培養中對抗 SARS-CoV-2、人類冠狀病毒 NL-63 和人類冠狀病毒 229E 中具有高效性,這些都是非常不同的人類冠狀病毒。這些結果表明,儘管現場有 SARS-CoV-2 進化的新變體,該藥物仍將保持活性,並確實證明了我們臨床藥物候選 NV-CoV-2 的泛冠狀病毒活性。
此外,虛擬病毒研究還顯示,NV-CoV-2 可中和細胞外部的病毒顆粒本身,從而驗證我們的設計機制。
納米殺菌劑有限公司(美國紐約證券交易所:NNVC)(「公司」)是基於新型納米醫學技術開發高效抗病毒療法的領導者,今天宣布,其泛冠狀病毒 COVID-19 藥物候選 NV-CoV-2 在標準細胞培養偽病毒測試中發現對 SARS-CoV-2 有效,證明該藥物確實具有廣譜泛型泛型冠狀病毒活性。這種泛型冠狀病毒活性意味著,儘管 SARS-CoV-2 的變種在現場發展,儘管 SARS-CoV-2 變種在現場發展,這是一種對抗當前全球大流行的非常受歡迎的特徵。
在此測試中,候選藥 NV-CoV-2 和 SARS-CoV-2 病毒的 Spike 抗原 S1 特有的陽性對照抗體都抑制了細胞培養研究中 SARS-CoV-2 偽病毒的感染,幾乎具有相同的基線水平。
我們現在已證明,NV-CoV-2 在細胞培養中對抗 SARS-CoV-2、人類冠狀病毒 NL-63 和人類冠狀病毒 229E 中具有高效性,這些都是非常不同的人類冠狀病毒。這些結果表明,儘管現場有 SARS-CoV-2 進化的新變體,該藥物仍將保持活性,並確實證明了我們臨床藥物候選 NV-CoV-2 的泛冠狀病毒活性。
此外,虛擬病毒研究還顯示,NV-CoV-2 可中和細胞外部的病毒顆粒本身,從而驗證我們的設計機制。
已翻譯
1
1
$Adamas Pharmaceuticals Inc(ADMS.US$
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). The first CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022.
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy; and Osmolex ER (amantadine) extended release tablets, approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
"This acquisition represents a significant step to further build a strong and diverse Parkinson's disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI's growth momentum so that more patients can benefit from access to Adamas' innovative neurological therapies."
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). The first CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022.
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy; and Osmolex ER (amantadine) extended release tablets, approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
"This acquisition represents a significant step to further build a strong and diverse Parkinson's disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI's growth momentum so that more patients can benefit from access to Adamas' innovative neurological therapies."
1
1
stock related to bitcoin gonna be green if btc stay above 56k ![]()
$Sphere 3d(ANY.US$
$Bit Digital(BTBT.US$
$BIT Mining(BTCM.US$
$Sphere 3d(ANY.US$
$Bit Digital(BTBT.US$
$BIT Mining(BTCM.US$
5
1
6
1
已翻譯
2
1
maxshen8 樓主 上了贼船888 : 新聞基於首次公開招股新聞